NLRP3 and neoplasm: In accordance, upon using an NLRP3 inhibitor, BAY117082, the NLRP3 inflammasome components expression and activation were inhibited, resulting in the reduction in OSCC cell viability in vitro and a reduction in tumour mass in vivo mouse models [176].